Two- or multidrug regimens prescribed to 93 patients with non-tuberculous mycobacterial pulmonary disease at any time within the total of 13 quarters
| NTM-specific drug regimens | Number of quarters prescribed | Number of patients# |
| Azithromycin + rifabutin + ethambutol | 13 | <5 |
| Clarithromycin + ethambutol | 13 | 24 |
| Clarithromycin + rifabutin + ethambutol | 13 | 14 |
| Clarithromycin + rifampicin + ethambutol | 13 | 18 |
| Rifabutin + ethambutol | 13 | 5 |
| Clarithromycin + rifabutin + prothionamide | 11 | <5 |
| Clarithromycin + rifabutin | 6 | 10 |
| Clarithromycin + ciprofloxacin | 5 | <5 |
| Rifampicin + ethambutol | 5 | 9 |
| Rifampicin + isoniazid + ethambutol | 5 | <5 |
| Moxifloxacin + ethambutol | 4 | <5 |
| Azithromycin + rifampicin + ethambutol | 3 | <5 |
| Azithromycin + ethambutol | 3 | <5 |
| Clarithromycin + moxifloxacin + ethambutol | 3 | <5 |
| Clarithromycin + prothionamide | 3 | <5 |
| Clarithromycin + rifampicin | 3 | 5 |
| Moxifloxacin + ethambutol | 3 | <5 |
| Rifampicin + prothionamide + ethambutol | 3 | <5 |
| Clarithromycin + ciprofloxacin + ethambutol | 2 | <5 |
| Clarithromycin + ciprofloxacin + rifabutin | 2 | <5 |
| Clarithromycin + ciprofloxacin + rifabutin + ethambutol | 2 | <5 |
| Clarithromycin + levofloxacin + rifampicin + ethambutol | 2 | <5 |
| Clarithromycin + levofloxacin + ethambutol | 2 | <5 |
| Clarithromycin + moxifloxacin + rifampicin | 2 | <5 |
| Clarithromycin + moxifloxacin + rifampicin + ethambutol | 2 | <5 |
| Clarithromycin + rifampicin + isoniazid + ethambutol | 2 | <5 |
| Moxifloxacin + rifabutin + ethambutol | 2 | <5 |
| Levofloxacin + rifabutin + isoniazid + ethambutol | 1 | <5 |
| Levofloxacin + rifampicin + isoniazid + ethambutol | 1 | <5 |
NTM: non-tuberculous mycobacteria. #: number of patients does not equal 100% because regimens may have changed from quarter to quarter.